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Abstract 
The purpose of this study was to investigate the effects of Montmorency tart cherry juice (MC) 
on nitric oxide (NO) biomarkers, vascular function and exercise performance in trained cyclists. 
In a randomized, double blind, placebo (PLA) – controlled, crossover study, 10 trained cyclists 
(mean ± SD; V̇O2peak 59.0 ± 7.0 ml/kg/min) acutely ingested 30 mL of either MC or PLA and 
completed a 6 min moderate- and severe-intensity cycling bout 1.5 h post ingestion on two 
occasions for each experimental condition.  The severe-intensity cycling test was continued to 
exhaustion on one occasion and immediately followed by a 60 s all-out sprint on the other 
occasion.  Blood pressure, pulse wave measures, tissue oxygenation index and plasma [NO2
-] 
were assessed pre and 1.5 h post ingestion.  Time to exhaustion was not different between 
conditions (P > 0.05), but peak power over the first 20 s (363 ± 42 vs. 330 ± 26 W) and total 
work completed during the 60 s all-out sprint (21 ± 3 vs. 19 ± 3 kJ) were 10% higher in the 
MC trial compared to the PLA trial (P < 0.05). Systolic blood pressure was 5 ± 2 mmHg lower 
1.5 h post MC supplementation compared to PLA supplementation (P < 0.05).  There were no 
differences in pulse wave measures, plasma nitrite concentration or tissue oxygenation index 
between the MC and PLA trials (P > 0.05). These results suggest that acute supplementation 
with MC can lower blood pressure and improve some aspects of exercise performance, 
specifically end-sprint performance, in trained cyclists.   
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Introduction  1 
Montmorency tart cherries (MC) are a rich source of polyphenols 1-3 including the flavonoids 2 
isorhamnetin, kaempferol, quercetin, catechin and anthocyanins 4,5.  It has been well 3 
documented that these plant compounds are associated with beneficial anti-inflammatory 6, 4 
antioxidant 7 (AOX), immunomodulatory and vasodilatory properties 8.  Previous studies 5 
demonstrated the positive effects of MC concentrate on indices of cardiovascular function that 6 
included increased cell migration 9, cerebral blood flow 10 and reduced systolic blood pressure 7 
10,11.  These effects might be mediated, in part by the ability of polyphenols to facilitate 8 
endothelial nitric oxide synthase (eNOS) phosphorylation, thereby increasing endogenous 9 
nitric oxide (NO) production 12, however, an increase in NO biomarkers has not been 10 
demonstrated with polyphenol-rich MC.   11 
It is possible that the improvements observed in vascular function following MC 12 
supplementation may help overcome any potential circulatory limitations that might contribute 13 
to exercise fatigue and cessation 13. Furthermore, increased blood flow has been reported to 14 
increase the oxidative energy contribution over the initial stages of exercise and to lower the 15 
development of the V̇O2 slow component (a progressive increase in O2 uptake (V̇O2) as high 16 
intensity exercise is continued 14.  Therefore, supplementation with MC might have the 17 
potential to improve aspects of the dynamic V̇O2 response during exercise. Consequently, MC 18 
might have a positive effect on athletic activities where the rate of blood flow and cardiac 19 
output are important determinants of cardiovascular performance, by acting on endothelial 20 
function.  Further to these mechanisms, quercetin (which is reported to be present in MC 15) 21 
binds and antagonises the adenosine receptor, which could improve performance in a caffeine-22 
like manner 16. Also, MC concentrate is rich in AOX compounds which may have the ability 23 
to augment performance 17.  24 
Despite the potential AOX and vasodilatory properties of tart cherries, to date, only two studies 25 
have investigated the effect of tart cherry supplementation on continuous exercise capacity and 26 
performance.    Clifford and colleagues 18 investigated the influence of different sources of 27 
polyphenols on sub-maximal cycling and time trial performance.  Supplementation with 200 28 
mg of CherryActive® capsules which contained 216 mg of polyphenols for three days, did not 29 
improve cycling time trial performance, heart rate, respiratory exchange ratio, gross 30 
mechanical efficiency, oxygen consumption, or blood [lactate] in moderately trained cyclists 31 
(V̇O2peak 52.4 ± 8.7 ml/kg/min). In contrast, when participants were supplemented with 32 
CherryPURE® capsules for 10 days, half-marathon completion times were 13% faster and 33 
there was a smaller deviation from predicted race pace compared to the placebo trial in trained 34 
runners 19, although the mechanism for this improvement was not elucidated.   Furthermore, 35 
there are several limitations of this study that indicate the results should be interpreted with a 36 
degree of caution. Firstly, an independent study design was utilized where participants were 37 
matched based on average reported race pace and as a result some variability associated with 38 
participant pairing may have been possible.  Secondly, differences in aerobic state of training 39 
beyond the study inclusion/exclusion criteria may also have been a source of variability in 40 
study cohort recruitment.  Notwithstanding the limitations of this study, similar performance-41 
enhancing findings have been reported in other studies where polyphenolic content of a fruit-42 
derived supplement is similar to tart cherries 20,21. Kang and colleagues 20 reported that 43 
oligomerized lychee fruit extract increased the anaerobic threshold by 7.4% (1.8, 13.0). 44 
Interestingly, these results suggest that a polyphenol-containing supplement and typical AOXs 45 
might have different mechanisms of action and that the endurance-promoting effect of 46 
oligomerized lychee fruit extract may not directly come from the scavenging of free radicals 47 
but might be attributed to other non-AOX properties of polyphenols.  More recently, Cook et 48 
al. 21 reported that following a seven-day intake of New Zealand blackcurrant extract, there 49 
was a significant improvement in cycling time-trial performance by 2.4%, coupled with 50 
increased fat oxidation. The authors speculated that this improvement may have been as a result 51 
of improved endothelial function and increased peripheral blood flow 52 
Although the potential beneficial role of MC in expediting exercise recovery has been widely 53 
demonstrated 22,23, it is still debated as to whether acute MC supplementation can improve 54 
endurance exercise performance.  Given that the majority of polyphenol compounds are either 55 
absorbed or excreted quickly 9,10,24, consequently it makes the argument that a 10-day 56 
supplementation period used in a previous study 19 is not necessary to observe improvements 57 
in performance in trained individuals.   Furthermore, the potential mechanisms that might 58 
underpin any ergogenic effects of tart cherry consumption are yet to be fully resolved. 59 
Therefore, the purpose of this study was to investigate the effects of acute tart cherry 60 
supplementation on plasma NO2
- concentration ([NO2
-]), a sensitive marker of NOS activity 25, 61 
as well as blood pressure, V̇O2 kinetics, muscle oxygenation and exercise performance using a 62 
double – blind cross-over experimental study design. We also used near-infrared spectroscopy 63 
to provide insight into the matching between skeletal muscle O2 delivery and utilisation 
26 and, 64 
therefore, the potential mechanisms for any improvement in V̇O2 kinetics or exercise 65 
performance following acute tart cherry supplementation.   66 
Methods 67 
Participants 68 
Eleven trained male cyclists volunteered to take part in the study, but one participant withdrew 69 
after the second study day (mean ± SD age; 28 ± 7 years, stature 1.83 ± 0.06 m, body mass 70 
78.0 ± 8.5 kg and V̇O2peak 59.0 ± 7.0 ml/kg/min). Exclusion criteria for the study were: V̇O2peak 71 
< 50 ml/kg/min (determined on visit 1), smoking, food allergy (as discussed with research 72 
team), history of gastrointestinal, renal or cardiovascular disease and current use of any food 73 
supplementations. All participants provided written, informed consent prior to the 74 
commencement of the study.  For 24 h prior to and for each of the testing days, participants 75 
were asked to avoid strenuous exercise, alcohol, caffeine, nutritional supplements and any anti-76 
inflammatory drugs. Participants were instructed to follow a low phenolic diet for 24 h prior to 77 
each arm of the trial by avoiding fruits, vegetables, tea, coffee, alcohol, chocolate, cereals, 78 
wholemeal bread, grains and spices and were asked to refrain from strenuous exercise.  79 
Compliance with the dietary restrictions was monitored with a standardised, self-reported 80 
dietary record.  Participants were asked to arrive at the laboratory in a rested and fully hydrated 81 
state, ≥10 h postprandial.  All tests were performed at the same time of day.  The study was 82 
conducted in accordance with the Helsinki Declaration and ratified by the University’s 83 
Research Ethics Committee. 84 
Study Design 85 
Participants were required to report to the laboratory on five occasions over a 4-5 week period 86 
to complete the experimental testing (1 familiarization / V̇O2peak visit and 4 experimental visits).  87 
On the first visit to the laboratory, participants completed a ramp incremental exercise test for 88 
determination of the gas exchange threshold (GET) and peak V̇O2 (V̇O2peak).  Participants were 89 
also familiarized with the two exercise performance tests employed in the study on this visit to 90 
avoid any order effect on the performance results as a consequence of a potential “learning 91 
effect”.  Participants then returned to the laboratory on visits 2, 3, 4 and 5 to complete the 92 
experimental testing (MC × 2 trials, PLA × 2 trials).  During these tests, resting blood pressure, 93 
arterial stiffness, pulmonary V̇O2 kinetics during moderate and severe intensity exercise, 94 
muscle oxygenation, and exercise performance were assessed, and venous blood samples were 95 
obtained.  The MC concentrate and placebo (PLA) drinks were administered in a randomized 96 
order as part of a double–blind, crossover experimental design.  Each supplementation day was 97 
separated by at least 3 days, but no more than 7 days. 98 
Incremental Test.   99 
During the first laboratory visit, participants completed a ramp incremental cycle test on an 100 
electronically braked cycle ergometer (Lode Excalibur Sport, Groningen, The Netherlands).  101 
Initially, participants performed 3 min of baseline cycling at 0 W, after which the work rate 102 
was increased by 30 W/min until the limit of tolerance.  The participants cycled at a self-103 
selected pedal rate, which, along with saddle and handle bar heights and configuration, was 104 
recorded and reproduced in subsequent tests.  Breath-by-breath pulmonary gas exchange data 105 
were collected continuously during the incremental tests and averaged over consecutive 10 s 106 
periods.  The V̇O2peak was taken as the highest 30 s rolling mean value attained prior to the 107 
participant’s volitional exhaustion in the test.  The GET was determined as 1) the first 108 
disproportionate increase in CO2 production (V̇CO2) from visual inspection of individual plots 109 
of V̇CO2 and V̇O2, and an increase in expired ventilation V̇E/ V̇O2 with no increase in V̇E/ V̇CO2.  110 
The work rate that would require 90% of the GET (moderate – intensity exercise) and 70% Δ 111 
(GET + 70% of the difference between the work rate at the GET and V̇O2peak; severe intensity 112 
exercise) were calculated.  The V̇O2 peak attained in the ramp incremental test was 4.56 ± 0.3 113 
l/min, which equated to a relative V̇O2 peak of 59 ± 7 ml·kg−1·min−1. The work rates that 114 
corresponded to 90% GET and 70%Δ were 121 ± 19 and 303 ± 28 W, respectively.  The mean 115 
response time (MRT) for V̇O2 during ramp exercise was taken into account, specifically two-116 
thirds of the ramp rate was deducted from the work rate at GET and peak V̇O2 (i.e., 20W 27).   117 
 118 
Following the incremental test and a 45-minute rest, participants were familiarized with the 119 
exercise tests.  Participants completed a moderate- intensity and severe-intensity, step test 120 
finishing with an all-out sprint followed (after a 30-minute passive recovery period) by a 121 
severe-intensity constant-work-rate step exercise test to the limit of tolerance.  122 
Experimental tests.  123 
On all subsequent visits, participants were required to rest in a seated position for 10 min in an 124 
isolated room.  Thereafter, baseline blood pressure of the brachial artery was measured using 125 
an automated sphygmomanometer (M10-IT Omron Healthcare, UK) according to British 126 
Hypertension Society guidelines.  Additionally, pulse wave velocity and pulse wave analysis 127 
were determined by using Arterial Tonometry (SphygmoCor CPV system, ScanMed Medical, 128 
UK).  Three measurements were taken, and the mean of the measurements were calculated.  A 129 
venous blood sample was then collected into a lithium-heparin tube and centrifuged at 4,000 130 
rpm at 4°C for 10 min, within 2 min of collection.  Lithium-heparin plasma was subsequently 131 
extracted and immediately frozen at -80°C for later analysis of [NO2
-] in duplicate via ozone-132 
based chemiluminescence 29. 133 
 134 
Participants were then provided with standardised breakfast.  Descriptive measures and a 135 
Physical Activity Level of 1.7 was used to calculate the participant’s individual resting energy 136 
expenditure (Schofield Equation, 1985).  This subsequently identified the amount of cereal 137 
(Rice Snaps, Tesco, Manchester, UK) and semi-skimmed milk (1g/kg/bm) each individual 138 
needed to consume to meet 10% of their daily energy requirements.  This standardised fixed-139 
energy breakfast meal consisted of a cereal: milk ratio of 30 g: 120 ml and delivered fat, protein 140 
and carbohydrate with a macronutrient composition of 14, 14 and 72%, respectively 29.  One-141 
hour post breakfast consumption, participants received the intervention drink.  Ninety minutes 142 
after ingestion of the supplement, vascular measures were reassessed and participants 143 
completed one of the two cycle tests described below, as published pharmacokinetic data have 144 
shown that this time frame should coincide with peak plasma concentrations of phenolic acids 145 
following MC supplementation 9,11. 146 
 147 
The exercise protocol consisted of three “step” exercise tests including two moderate intensity 148 
step tests followed by one severe-intensity exercise bout.  All participants performed a total of 149 
four bouts of moderate intensity exercise and two bouts of severe-intensity exercise for each 150 
experimental condition; this protocol replicated previously work 30.  Each transition began with 151 
3 min of baseline cycling at 20 W before an abrupt transition to the target work rate.  Each 152 
moderate intensity bout lasted 6 min.  A passive recovery of 5 min separated the transitions.  153 
On two of the study visits (one occasion for each supplement), participants cycled for 6 min at 154 
a severe-intensity constant work rate (70% Δ), followed immediately by a 60 s all-out sprint at 155 
maximum effort.  The resistance on the pedals during this sprint was set using the linear mode 156 
of the Lode ergometer, so that each participant would attain the power output calculated to be 157 
50% Δ when considering the participants preferred cadence (linear factor = power/preferred 158 
cadence2).  Participants were provided with a 5 s countdown prior to the sprint.  On the other 159 
two study visits (one occasion for each supplement), the severe-intensity constant-work-rate 160 
bout was continued to the limit of tolerance. The time to task failure was used as a measure of 161 
exercise tolerance and was immediately recorded when the pedal rate fell by > 10 rpm below 162 
the required pedal rate. 163 
Treatments and dietary control 164 
Participants consumed either 60 ml of commercially available MC concentrate 165 
(CherryActive®, Hanworth, UK) or fruit-flavoured cordial in a double blind cross-over manner.  166 
The choice to use 60 ml was based on previous work that showed a greater uptake of 167 
anthocyanin and phenolic acids in vivo post-consumption when compared to a 30 ml dose 3,9,11.  168 
The concentrate was diluted with 100 ml of water prior to consumption.  The PLA supplement 169 
consisted of a commercially available, low fruit (<1%) cordial (Kia Ora, Coca Cola Enterprises, 170 
Uxbridge, UK) cordial mixed with water, whey protein isolate (Arla Foods Ltd., Leeds, UK) 171 
and maltodextrin (MyProtein Ltd., Northwich, UK), to match the MC concentrate for volume 172 
and macronutrient content (Energy = 204 kcal, volume = 60 ml, carbohydrates = 49 g, protein 173 
= 2.2 g and fat = 0 g). 174 
 175 
Prior to study commencement, it was explained to participants that the aim of the study was to 176 
investigate the effect of a fruit juice on vascular function.  As a result, they were unaware which 177 
beverage was the experimental drink. There were no adverse events reported in response to the 178 
intervention products. Subjects consumed all doses of the supplement for each experimental 179 
condition, and all participants complied with the low-polyphenolic experimental diet according 180 
to the food diaries. 181 
Measurements  182 
During all tests, pulmonary gas exchange and ventilation were measured breath-by-breath.  183 
Participants wore a nose clip and breathed through a low-dead-space, low-resistance 184 
mouthpiece-and-impeller turbine assembly. Following calibration according to manufacturer’s 185 
recommendations, the inspired and expired gas volume was continuously sampled at 100 Hz; 186 
gas concentration signals were continuously sampled at 100 Hz using paramagnetic (O2) and 187 
infrared (CO2) analyzers (Oxycon, Care Fusion, Rolle, Switzerland). For data analysis, the 188 
moderate bouts of exercise were exported in 10-s averages and then averaged for all bouts.  189 
End-exercise V̇O2 (average over the last 30 s and 60 s of the bout), baseline V̇O2 (average over 190 
the 60 s prior to exercise) and the amplitude (the difference between the end-exercise and 191 
baseline V̇O2) were analysed.  For the severe bouts of exercise, the data were exported in 10-s 192 
averages and then all bouts were averaged.  Baseline V̇O2 (average over the 60 s prior to 193 
exercise), the V̇O2 at 120 s (the average from 110 s to 130 i.e. 120 s +/- 10 s) and the end-194 
exercise V̇O2 (the average over the last 30 s of the bout) were identified. The peak V̇O2 was 195 
identified using the end- exercise V̇O2. Furthermore, the difference between the baseline and 196 
120 s V̇O2 provides a surrogate for the fundamental amplitude whilst the difference between 197 
V̇O2 at 120 s and end-exercise (exhaustion) was used as a surrogate of the V̇O2 slow component. 198 
The oxygenation status of the vastus lateralis of the right leg was monitored near-infrared 199 
spectroscopy system (NIRS; INVOS 5100C, Somanetics, Troy, MI, USA) at two different 200 
wavelengths (765 nm and 855 nm). The intensity of the transmitted light was continuously 201 
recorded at 1 Hz. Based on the absorption and scattering coefficients of light at each 202 
wavelength, determined by Beer–Lambert Law, concentrations were estimated for oxy (HbO2), 203 
deoxy (HHb), and total haemoglobin.   The leg was initially cleaned around the belly of the 204 
muscle, and the optodes were placed 20 cm above the fibular head.  The probes were secured 205 
to the skin surface and covered with an elasticized, tensor bandage to minimize the influence 206 
of extraneous light, and to avoid movement of the probe relative to the skin, while allowing 207 
unrestricted movement.  The NIRS data were acquired continuously throughout the exercise 208 
protocol and output every 5 s and recorded for later offline analysis.  The NIRS data output 209 
was time stamped at the start of each task segment to assure that data corresponded to the 210 
relevant period of task performance. To provide information on muscle oxygenation, NIRS 211 
data was averaged at the time points of interest and relative concentration changes in HbO2 and 212 
HHb were calculated.  213 
The tissue oxygenation index (TOI) was calculated using the following equation 30 214 
TOI =    [HbO2]  215 
 [HbO2] + [HHb] × 100                 Equation 1 216 
Pulse wave velocity (PWV) and pulse wave analysis (PWA) were determined by using Arterial 217 
Tonometry (SphygmoCor CPV system, ScanMed Medical, UK).  The aortic pulse waveform 218 
and augmentation index were derived at the radial artery and PWV was determined between 219 
carotid and femoral sites.  A pencil-type probe was used for all measurements and was held at 220 
the base of the neck over the carotid artery and at the inguinal crease over the right femoral 221 
artery.  Recordings were taken when a reproducible signal was obtained with a high amplitude 222 
excursion.  The distance between carotid and femoral sites was measured and 223 
electrocardiogram gating permitted the time lapse between pulse waves at the carotid and 224 
femoral sites to be calculated. Inter- and intra-trial % coefficient of variation (CV) for this 225 
method was 3.3 and 3.1%, respectively. 226 
During the exercise trials, a blood sample was collected from a fingertip into a capillary tube 227 
at baseline, over the 20 s preceding the step transition in work rate, the 20 s preceding the 228 
completion of 360 s of moderate- and severe-intensity cycling exercise, immediately following 229 
the 60-s all-out sprint and immediately after exhaustion during the severe-intensity constant-230 
work-rate trial.  These whole blood samples were analysed to determine blood lactate (Biosen 231 
C_Line, EKF Diagnostic, Barleben, Germany).  Intra-sample coefficient of variation for this 232 
instrument was 1.8%. 233 
Plasma [nitrate] and [nitrite] determination 234 
All glassware, utensils, and surfaces were rinsed with deionized water to remove residual NO 235 
intermediates prior to [NO2
-] and [NO3
-] analysis.  Plasma samples were deproteinized using 236 
zinc sulfate/sodium hydroxide precipitation prior to determination of [NO3
-]. Firstly, 500 μL 237 
of 0.18 N NaOH was added to 100 µL of sample followed by 5 min incubation at room 238 
temperature.  Subsequently, samples were treated with 300 μL aqueous ZnSO4 (5% w/v) and 239 
vortexed for 30 s before undergoing an additional 10 min incubation period at room 240 
temperature. Samples were then centrifuged at 4,000 rpm for 5 min, and the supernatant was 241 
removed for subsequent analysis.  The [NO3
-] of the deproteinized plasma sample was 242 
determined by its reduction to NO in the presence of 0.8 % (w/v) VCl3 in 1 M HCl within an 243 
air-tight purging vessel.  Plasma samples were introduced to the vessel via 50 µL injections 244 
into the septum at the top of the vessel.  The spectral emission of electronically excited nitrogen 245 
dioxide, derived from the reaction of NO with ozone, was detected by a thermoelectrically 246 
cooled, red-sensitive photomultiplier tube housed in a Sievers gas-phase chemiluminescence 247 
nitric oxide analyzer (Sievers NOA 280i. Analytix Ltd, Durham, UK). The [NO3
-] was 248 
determined by plotting signal (mV) area against a calibration plot of sodium nitrate standards.  249 
The [NO2
-] of the undiluted (non-deproteinized) plasma was determined by its reduction to NO 250 
in the presence of glacial acetic acid and aqueous NaI (4% w/v) from sodium nitrite standards.  251 
100 µL injections were used for plasma [NO2
-] determination.   252 
Statistical Analysis 253 
Statistical analysis was performed using PASW Statistics 21.0 for Windows (SPSS, Inc., 254 
Chicago, IL.).  All group characteristics were reported as means ± standard deviations, unless 255 
otherwise stated.  A 2 (MC vs. PLA) × 2 (pre vs. post) repeated measures analysis of variance 256 
(ANOVA) was employed to assess between–intervention differences in V̇O2, NIRS–TOI, 257 
blood pressure, arterial stiffness and lactate. Mauchly’s Test of Sphericity was used to check 258 
homogeneity of variance for all ANOVA analyses and where necessary, violations of the 259 
assumption were corrected using the Greenhouse–Geisser adjustment. Significant main effects 260 
were followed up using LSD post hoc analysis.  Exercise performance and NO2− and NO3- 261 
were analysed using a paired samples t-test. Statistical significance was accepted when P < 262 
0.05. 263 
Results  264 
Eleven physically active males volunteered to take part in the study, but one participant 265 
voluntarily withdrew after the second study day (n=10).   266 
Pulmonary V̇O2 kinetics 267 
The pulmonary V̇O2 data for the moderate- and severe-intensity cycle tests are reported in Table 268 
1.  There were no significant between-supplement differences for the baseline and end-exercise 269 
V̇O2 during the moderate-intensity step exercise tests (P > 0.05).  Accordingly, the fundamental 270 
V̇O2 amplitude was not significantly different between the conditions (0.55 ± 0.09 and 0.60 ± 271 
0.07 l/min with MC concentrate and PLA respectively, P > 0.05). 272 
 273 
The baseline and end-exercise V̇O2 during severe-intensity exercise were not significantly 274 
impacted by the dietary interventions employed in this investigation (P > 0.05 for all 275 
comparisons).  The V̇O2 at exhaustion was not significantly different between experimental 276 
conditions and was also not significantly different from the V̇O2peak attained in the ramp 277 
incremental test (P > 0.05).  No significant differences were reported between MC and PLA in 278 
V̇O2 amplitudes from baseline to 120 s of exercise.  No differences in V̇O2 slow component 279 
were observed across the experimental conditions (Table 1). There were no differences in 280 
V̇CO2 between the conditions during moderate- or severe-intensity cycle exercise (P > 0.05 for 281 
all comparisons). 282 
 283 
  284 
Table 1 - Pulmonary V̇O2 measures during moderate- and severe-intensity cycle exercise after 285 
MC and PLA supplementation. 286 
 MC Concentrate Placebo 
 Moderate-intensity exercise 
V̇O2, l/min   
  Baseline 1.67 ± 0.09 1.68 ± 0.11 
  End-exercise 2.22 ± 0.09 2.28 ± 0.10 
Fundamental amplitude, l/min 0.55 ± 0.09 0.60 ± 0.07 
 Severe – intensity exercise 
V̇O2, l/min   
  Baseline 1.72 ± 0.04 1.74 ± 0.04 
  360 s 4.42 ± 0.12 4.36 ± 0.10 
  Exhaustion 4.50 ± 0.11 4.44 ± 0.09 
Fundamental amplitude, l/min 2.43 ± 0.10 2.37 ± 0.09 
Slow component amplitude l/min 0.27 ± 0.02 0.35 ± 0.03 
All values are means ± SEM. 287 
 288 
Exercise performance  289 
The time to exhaustion during the severe-intensity constant-work-rate cycle trials (the exercise 290 
tolerance test) are presented in Fig 1 and while the power profiles for the two experimental 291 
conditions during the 60-s all-out sprint that followed the 6-min bout of severe intensity 292 
exercise (the exercise performance test) are shown in Fig 2.  There were no significant 293 
differences in time to exhaustion during the exercise tolerance test between the MC (772 ± 34 294 
s) and the PLA conditions (733 ± 34 s, P = 0.323).  A significant main effect for supplement 295 
was observed for the peak power over the first 20 s and total work completed during the 60-s 296 
all-out sprint (P < 0.002).  Follow-up analyses demonstrated that, compared with PLA, MC 297 
concentrate supplementation increased the test peak power by 9.5% (363 ± 42 vs. 330 ± 26 W, 298 
P = 0.034; Fig 2) and the total work completed during the 60 s sprint by 10% between 299 
conditions (21 ± 3 vs. 19 ± 3 kJ, P = 0.021).  300 
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Fig 1 - Time to exhaustion during severe-intensity constant –work-rate cycle exercise after MC 302 
concentrate and placebo with individual responses to supplementation included. Data presented 303 
as means ± SEM. 304 
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Fig 2 - Group mean power profiles during a 60-s all-out cycle sprint completed immediately 307 
after 6-min of severe-intensity cycle exercise following MC concentrate and PLA 308 
supplementation.  Note significant increase in peak and mean power output during the 60s- all-309 
out sprint after MC concentrate compared to PLA.  Data presented as means ± SEM. 310 
 311 
NIRS  312 
The tissue oxygenation index data during moderate- and severe-intensity cycle exercise with 313 
PLA and MC supplementation are reported in Table 2.  There were no significant differences 314 
between the experimental conditions during the moderate or severe-intensity exercise (P > 315 
0.05).   316 
 317 
Table 2 - Near – infrared spectroscopy measures during moderate- and severe intensity cycle 318 
exercise after MC and PLA supplementation. 319 
 MC Concentrate Placebo 
 Moderate- intensity exercise 
Tissue oxygenation index, % 
  Baseline 67 ± 2 67 ± 2 
  120 s 67 ± 2 66 ± 2 
  End-exercise  66 ± 3 65 ± 1 
    
Severe-intensity exercise 
Tissue oxygenation 
index, % 
  
  Baseline 66 ± 3 68 ± 3 
  120 s 52 ± 4 54 ± 4 
  End- exercise 49 ± 3 48 ± 5 
All values are means ± SEM.   320 
 321 
Vascular measures 322 
There was a significant interaction effect for supplement on SBP (P < 0.05), with follow-up 323 
analyses showing that SBP was lower 1.5 h post MC supplementation, with reductions of 5 ± 324 
2 mmHg compared to the placebo trial.  No other vascular variables (DBP, mean arterial 325 
pressure (MAP), PWV, augmentation index (AIx) and AIx corrected for HR at 75 bpm) were 326 
altered after consumption of the MC concentrate compared to the placebo treatment.  The 327 
absolute values for all variables are presented in Table 3. 328 
 329 
  330 
Table 3 - Acute effects of tart Montmorency cherry juice and PLA on vascular function. 331 
Variable Baseline 1.5 h Post 
SBP (mmHg) 
60 ml MC 
PLA 
 
118 ± 3 
119 ± 3 
 
115 ± 2* 
120 ± 3 
DBP (mmHg) 
60 ml MC 
PLA 
 
69 ± 2 
67 ± 3 
 
68 ± 3 
68 ± 2 
PWV (m/s) 
60 ml MC  
PLA 
 
6.0 ± 0.3 
6.0 ± 0.3 
 
5.9 ± 0.4 
6.0 ± 0.3 
MAP (mmHg)   
60 ml MC 85 ± 2 84 ±2 
PLA 83 ±2 85 ± 3 
AIx (%) 
60 ml MC 
PLA 
 
9.4 ± 2.0 
8.3 ± 2.0 
 
9.1 ± 1.7 
7.5 ± 1.6 
AIx @ 75bpm (%) 
60 ml MC 
PLA 
 
9.2 ± 2.3 
9.8 ± 1.8 
 
9.9 ± 2.2 
10.3 ± 2.3 
All values are means ± SEM (n=10). * Significant difference between Placebo and cherry 332 
concentrate treatment (2-factor repeated measures ANOVA) P < 0.05: SBP, systolic blood 333 
pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; PWV, pulse wave 334 
velocity; AIx, augmentation index; MC, Montmorency cherry concentrate; PLA, Placebo. 335 
 336 
Plasma [NO2−] and [NO3−] 337 
Due to sampling error, blood was analysed in 8 participants.  The plasma [NO2
−] and [NO3
−] 338 
for the MC and PLA conditions are reported in Table 4.  There were no changes for NO2
− or 339 
NO3
− in the MC supplemented trial when compared to the placebo (P > 0.05). 340 
 341 
  342 
Table 4 - Plasma [NO2
−] and [NO3
−] at baseline and 1.5 h following MC concentrate and PLA 343 
supplementation. 344 
 MC Concentrate PLA 
 Pre Post Pre Post 
Plasma [NO2−] nM 65 ± 9 68 ± 8 63 ± 7 63 ± 9 
Plasma [NO3−] µM 19 ± 2 18 ± 2 20 ± 2 18 ± 2 
All values are means ± SEM (n=8). MC, Montmorency Cherry; PLA, Placebo. 345 
Lactate  346 
There was no treatment or treatment × time interaction effect observed in blood [lactate], 347 
however there was a significant time effect identified during both the exercise performance and 348 
tolerance test (P < 0.001).   No other differences were reported.  Absolute values are presented 349 
in Table 5.   350 
 351 
  352 
Table 5 - Acute effects of tart MC and PLA on lactate following exercise performance and 353 
tolerance test. 354 
 Time points 
 1 2 3 4 5 
Lactate 
(mmol/L) 
Exercise performance test 
 
60 ml MC 
PLA 
 
1.7 ± 0.2† 
1.7 ± 0.2† 
 
2.3 ± 0.2† 
2.2 ± 0.2† 
 
2.6 ± 0.2† 
2.9 ± 0.4† 
 
9.5 ± 0.8† 
10.0 ± 0.8† 
 
10.6 ± 0.6† 
11.6 ± 0.8† 
 Exercise tolerance test 
 
60 ml MC 
PLA 
 
2.0 ± 0.1† 
2.1 ± 0.2† 
 
2.2 ± 0.2† 
2.4 ± 0.2† 
 
2.6 ± 0.2† 
2.7 ± 0.2† 
 
9.8 ± 0.7† 
9.9 ± 0.5† 
 
12.5 ± 0.8† 
11.2 ± 0.7† 
 355 
All values are means ± SEM (n=10).  † Significant difference between time points from 356 
baseline, P < 0.05.   357 
 358 
Discussion 359 
The principal novel findings from this study are that, compared with an energy-matched 360 
placebo, acute MC supplementation enhanced exercise performance, specifically end-sprint 361 
performance in trained cyclists, in the absence of changes in V̇O2, plasma [NO2-] or muscle 362 
oxygenation variables. In addition, SBP was lower 1.5 h post MC consumption but not with 363 
PLA.  364 
Influence of MC supplementation on performance  365 
In the current study, peak power output and total work done during a 60-s sprint completed 366 
immediately following 6 min of severe-intensity exercise was increased by 9.5 and 10% 367 
respectively, following MC relative to the PLA supplementation.  While tart cherry 368 
supplementation has been shown to improve exercise recovery 22,23, decrease markers of 369 
inflammation and oxidative stress 1,3, studies investigating the effects of tart cherries on 370 
exercise performance are limited and equivocal.  Of the two studies investigating the influence 371 
of MC supplementation on exercise performance to date, one reported improved performance 372 
in males completing a half marathon (21.1km) run, as evidenced by a faster overall race pace 373 
compared to the PLA group 19. While Levers et al. designed an experiment to assess the 374 
influence of ingesting 480 mg of powdered tart cherries for 10-days, including supplementation 375 
on race day up to 48-hr post-run, we investigated the effects of a single dose (60 ml) of MC 376 
concentrate on exercise performance using a cross over study design.  Despite the differences 377 
in dosing strategies, both studies reported improvements in performance in trained participants.  378 
Therefore, our findings suggest that acute as well as chronic supplementation with MC 379 
concentrate has the potential to improve endurance performance, specially end-sprint 380 
performance. Conversely, an earlier study by Clifford and colleagues 18 reported no difference 381 
in time trial performance in moderately-trained individuals following the ingestion of 200 mg 382 
of powdered tart cherries for 3-days.  These conflicting findings are likely linked to the 383 
differences in dosing procedures (480mg of providing 991mg of phenolic compounds versus 384 
200mg of providing 216 mg of polyphenols) and exercise performance tests (20 km cycling 385 
time trial versus half marathon). There were no differences observed for time to exhaustion 386 
between the MC and the PLA trial in the current study.  There remains a debate surrounding 387 
the applicability and repeatability of the time to exhaustion test 31.  However, a recent addition 388 
to the literature highlighted that cycling performance is superior for time to exhaustion versus 389 
time trial and therefore should not be disregarded as a useful measure of performance in the 390 
laboratory 32.   391 
There were no changes in V̇O2, blood [lactate] or muscle oxygenation in the current study 392 
suggesting that the ergogenic effects of MC supplementation were not linked to improved 393 
metabolic responses or matching of muscle O2 supply relative to O2 demand. Furthermore, 394 
plasma [NO2
-] was not different between the two trials and since plasma [NO2
-] is a sensitive 395 
biomarker of eNOS activity 25, the performance improvements with MC supplementation 396 
might be independent of NO-mediated signalling.  It is more likely that the enhanced 397 
performance might be mediated through the AOX and vasodilatory properties of polyphenol-398 
rich MC.  When undertaking high intensity exercise, ROS are produced causing cellular 399 
damage and oxidative stress 33. AOX have the ability to prevent or reduce the extent of 400 
oxidative damage to other molecules.  It is therefore possible that the AOX effects of MC 401 
concentrate were only significant at this time when skeletal muscle contractions were most 402 
likely to be compromised by increased oxidative stress 33.  In agreement, an investigation by 403 
MacRae and Mefferd 34 reported that the addition of a flavonoid quercetin to a liquid AOX 404 
supplement significantly enhanced the AOX effect of the supplement and resulted in a 3.1% 405 
performance improvement during a 30 km cycle time trial.  Hence, it is possible that a 406 
combination of AOX compounds may induce larger effects on exercise performance. Given 407 
that MC concentrate has been shown to possess numerous AOX and polyphenolic compounds 408 
1,2, it makes the argument tenable that the improvement in exercise performance in the current 409 
study might be as a result of these AOX compounds. It is worth commenting that MC 410 
supplementation could have prolonged the duration for which the participants were in the 411 
optimal cellular redox state for force production 35 such that when they were required to 412 
produce an all-out sprint, they produced a higher peak power and completed more work.  413 
Furthermore, this improvement in exercise performance might also be as a result of an increase 414 
in blood flow, as previous research has demonstrated the positive effects of MC 415 
supplementation on vascular function, 10,11 that may help to overcome any potential circulatory 416 
limitations following strenuous exercise, attenuating the diminishing O2 supply to the 417 
exercising muscles and maintaining force production during the final 60s 36.   418 
Influence of MC supplementation on plasma [NO2
−] 419 
Nitric oxide is a key regulator of vascular integrity.  This multifaceted physiological signalling 420 
molecule can be synthesized endogenously through NOS with plasma [NO2
-] reflecting NOS 421 
activity 25.  No significant difference in plasma [NO2
-] was reported between the MC and PLA 422 
trials in the current study.  This is somewhat in agreement with the findings from Keane and 423 
colleagues 11, where no main effect for plasma nitrate or nitrite was observed following 60 mL 424 
MC supplementation using an ELISA kit.  Importantly, the lack of a change in plasma [NO2
-] 425 
in the current study extends our previous findings by using a more sensitive method to detect 426 
plasma [NO2
-] in the nM range and this better reflects NOS activity than plasma [NO3
-] 25.  427 
Since trained endurance cyclists were recruited in the current study, and since endurance 428 
training increase NOS expression 37; it is likely that eNOS-derived NO is already functioning 429 
optimally in this cohort and therefore no changes were observed after MC supplementation.  It 430 
is also interesting to note, the resting plasma NO2
- levels are quite low in the current study when 431 
compared with previous literature 30, 38, this could be as a result of the strict dietary restrictions 432 
imposed on the participants on the day preceding the trial or a low intake of nitrate-rich foods 433 
in general.  434 
Influence of MC supplementation on blood pressure  435 
A primary outcome of enhanced NO synthesis is a reduction in blood pressure owing to NO-436 
induced smooth muscle relaxation 39.  The current study reported a significant reduction in SBP 437 
1.5 h post MC ingestion relative to placebo, however this augmented modulation occurred in 438 
the absence of changes in NO biomarkers.  These results are consistent with recent studies 439 
demonstrated that supplementation with the NOS substrates, L-Citrulline 30 or L-arginine 38, 440 
lowered blood pressure in the absence of a change in plasma [NO2
-].  Mechanistically, it would 441 
appear that the lowering of BP with acute MC supplementation in the current study is largely 442 
NO-independent and is more likely to be a function of the increase in circulating phenolic 443 
metabolites post MC ingestion 11. 444 
There was no change in arterial stiffness observed in the current study.  This observation is in 445 
line with previous studies reporting improved SBP following MC consumption in males with 446 
early hypertension 11 and middle aged adults 10, with no improvement in arterial stiffness.   It 447 
has previously been reported that concurrent improvements in all measures of vascular function 448 
are not always observed 40. Further research is required to investigate the mechanisms by which 449 
MC supplementation might positively affect vascular and other physiological responses. 450 
An acknowledged limitation of the current study is the lack of polyphenol analysis and 451 
oxidative stress biomarkers. Conceivably, there are a number of mechanisms that could 452 
contribute to the physiological effects exerted by MC and as such further research is needed to 453 
address the underlying mechanisms of these observations.  In addition, participants in the 454 
current study abided by strict dietary restrictions in the days preceding the trials and as a result, 455 
future work should attempt to investigate the potential synergetic effects of MC 456 
supplementation within habitual dietary practices.   457 
In conclusion, this study has shown that acute supplementation with MC juice can lower blood 458 
pressure and improve exercise performance, specifically end-sprint performance, in trained 459 
endurance cyclists.  There were no changes in plasma [NO2
-], pulmonary V̇O2, or muscle 460 
oxygenation after ingesting tart cherry juice so the improvements in blood pressure and 461 
exercise performance in this study might be mediated through the potent antioxidant properties 462 
of MC juice.  The results of this study suggest that supplementation with MC concentrate might 463 
represent, a practical, non-pharmacological, dietary intervention to reduce blood pressure and 464 
enhance end-sprint performance in trained individuals.  465 
Perspectives 466 
The concept of marginal gains has revolutionised many sports particularly if a sprint finish 467 
could potentially be the difference between winning and losing.  The improvement in exercise 468 
performance in the current study, which supports the supposition of Levers et al. 19, would 469 
prove advantageous in sporting situations where very little separates opponents.   After 470 
completing exercise that was deemed both mechanically and metabolically stressful, when 471 
participants were supplemented with MC, they performed better over a 60-s sprint. Tart cherry 472 
juice appears to provide a feasible alternative to pharmaceutical and therapeutic interventions 473 
in improving exercise performance. Importantly, regardless of the mechanism, these 474 
improvements in performance are of most interest to the athlete, applied coach or sports 475 
scientist.  Furthermore, the marked reductions in systolic blood pressure highlights the potential 476 
importance of MCs as an adjuvant in the management of hypertension, as evidenced previously 477 
by Keane and colleagues 10,11. 478 
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